Joseph A Tino, PhD
Affiliations: | 1982- | Chemistry | Bristol Myers Squibb |
Area:
medicinal chemistryGoogle:
"Joseph Tino"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Alex Nickon | research assistant | 1981-1982 | |
| Yoshito Kishi | grad student | 1982-1987 | Harvard & Radcliffe |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Liu Q, Batt DG, Weigelt CA, et al. (2020) Novel Tricyclic Pyroglutamide Derivatives as Potent RORγt Inverse Agonists Identified using a Virtual Screening Approach. Acs Medicinal Chemistry Letters. 11: 2510-2518 |
| Xiao HY, Li N, Duan JJ, et al. (2020) Biologic-like In Vivo Efficacy with Small Molecule Inhibitors of TNFα Identified Using Scaffold Hopping and Structure-Based Drug Design Approaches. Journal of Medicinal Chemistry |
| Srivastava AS, Ko S, Watterson SH, et al. (2020) Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK. Acs Medicinal Chemistry Letters. 11: 2195-2203 |
| Shi Q, Xiao Z, Yang MG, et al. (2020) Tricyclic Sulfones as Potent, Selective and Efficacious RORγt Inverse Agonists - Exploring C6 and C8 SAR Using Late-Stage Functionalization. Bioorganic & Medicinal Chemistry Letters. 127521 |
| Marcoux D, Beaudoin Bertrand M, Weigelt CA, et al. (2020) Annulation Reaction Enables the identification of an Exocyclic Amide Tricyclic Chemotype as Retinoic Acid Receptor-Related Orphan Receptor Gamma (RORγ/RORc) Inverse Agonists. Bioorganic & Medicinal Chemistry Letters. 127466 |
| Cherney RJ, Cornelius LAM, Srivastava A, et al. (2020) Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse Agonist. Acs Medicinal Chemistry Letters. 11: 1221-1227 |
| Marcoux D, Duan JJ, Shi Q, et al. (2019) Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt ‒ Identification of a Potent, Selective Series with Biologic-Like In Vivo Efficacy. Journal of Medicinal Chemistry |
| Watterson SH, Liu Q, Beaudoin Bertrand M, et al. (2019) Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid In Vivo Inactivation of Bruton's Tyrosine Kinase (BTK). Journal of Medicinal Chemistry |
| Yip SH, Wu DR, Li P, et al. (2018) Separation of Bruton's tyrosine kinase inhibitor atropisomers by supercritical fluid chromatography. Journal of Chromatography. A |
| Liu Q, Batt DG, Chaudhry C, et al. (2018) Conversion of carbazole carboxamide based reversible inhibitors of Bruton's tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series. Bioorganic & Medicinal Chemistry Letters |